Q-omics provides the consensus-scored WDR59 profile across patient tissues and cancer cell-line models. WDR59 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, WDR59 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, WDR59 RNA expression shows 20,243 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight READ, COAD, and ACC as cancer lineages where WDR59 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WDR59 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WDR59 survival associations across molecular data types. WDR59 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (8) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WDR59 RNA expression–survival associations across cancer types. High WDR59 expression shows unfavorable associations in BLCA, ACC, COAD and SKCM, but favorable associations in READ and UCS. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify READ as the clearest survival context for WDR59 RNA expression.
This table summarizes WDR59 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for WDR59. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WDR59 shows lower tumor expression in THCA, KICH and BRCA and higher tumor expression in COAD, HNSC and READ. The COAD box plot shows higher WDR59 RNA expression in tumor versus normal tissue (log2 FC = +0.868, t-test p < 0.001).
This table shows molecular features associated with WDR59 in patient tissues and cancer cell lines. In patient samples, WDR59 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, WDR59 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
